Virtual Library
Start Your Search
H. Wang
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 2
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-029 - Real World Report of Clinical Outcomes of Bevacizumab in First-Line or Later-Line Treatment for Patients with Advanced NSCLC (ID 8999)
09:00 - 09:00 | Author(s): H. Wang
- Abstract
Background:
Bevacizumab combined therapy has been demonstrated superior efficacy and well tolerability in first-line and later-line treatment by various scales of prospective control trials. But it is still lack of direct evidence endorsing bevacizumab as first-line (1L) over later-line (LL) use.
Method:
We retrospectively evaluated the effectiveness of bevacizumab contained therapy as 1L or LL treatment in patients with advanced NSCLC. Primary outcome was progression-free survival (PFS), and the secondary objectives were objective response rate (ORR), disease control rate (DCR) and safety. Subsequently, an exploratory analysis was conducted in subgroups regarding to patients drive genes status including EGFR and ALK.
Result:
From Jul. 2009 to Dec. 2016, a total of 159 patients with NSCLC were enrolled. Baseline characteristics were well balanced between 1L and LL groups. The median follow-up time was 10.7 months. Comparing to LL, the median PFS in 1L was significant longer (9.7 months vs 4.1 months, HR=0.28, 95% CI 0.15-0.52, P＜0.0001). Short term effects of ORR and DCR both had improved trends in 1L than LL. Interestingly in subgroups, WT group (median PFS 11.3 vs 3.4 months, HR 0.2, 95% CI 0.08-0.48, P<0.0001) and WT+UN group (median PFS 11.3 vs 3.4 months, HR 0.25, 95% CI 0.12- 0.51, P<0.0001) had better effectiveness as 1L than LL over the whole population. The ORR and DCR had consistently similar response in subgroups comparison (Table 1). There was no unexpected safety issue documented. Figure 1
Conclusion:
Although it was limited in retrospective design, this precious real world evidence indeed exhibited superior clinical effectiveness in first-line use of bevacizumab indicating a better choice rather than later line use, particularly to EGFR&ALK wild type or unknown patients.
-
+
P2.01-030 - Real World Study of Bevacizumab-Contained Regimen as First Line Therapy in Chinese Patients with Advanced NSCLC (ID 9019)
09:00 - 09:00 | Author(s): H. Wang
- Abstract
Background:
Bevacizumab has been demonstrated significant survival benefits in addition to chemotherapy in patients with advanced NSCLC from several large scale randomized control trials. We aimed to explore the clinical impact of first-line bevacizumab-contained regimen (B+) versus non-bevacizumab regimen (non-B) for patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC) in the real world setting.
Method:
From July 2009 to December 2016, patients with advanced NS-NSCLC who received first-line therapy with or without bevacizumab were retrospectively collected from Cancer Hospital Chinese Academy of Medical Sciences. Primary outcome was progression-free survival (PFS), and the secondary objectives were objective response rate (ORR), disease control rate (DCR) and safety. Meanwhile exploratory analysis was conducted in each sub-groups regarding to EGFR and ALK status.
Result:
149 patients met selection criteria, 62 in B+ group and 87 in non-B group. Chemotherapy was the based treatment in each group, 57/62 and 71/87 respectively. Median follow-up time was 10.7 months. The baseline characteristics were well balanced. In overall population, median PFS were significantly longer in B+ than in the non-B group: 9.7 vs 7.0 months, HR 0.52, 95% CI 0.30-0.91, P=0.0184. Both ORR and DCR had improved trends in B+ group. In wild type patients, median PFS of B+ group was 11.3 months compared with 5.5 months in the non-B group (HR, 0.43; 95% CI, 0.20-0.91; P=0.0234). In wild-type and unknown population, median PFS was 11.3 months (B+ group) comparing to 6.0 months (non-B group) (HR, 0.53; 95% CI, 0.28-1.02; P=0.0520). The ORR and DCR had consistently similar response in subgroups comparison (Table 1). Safety profile was acceptable in both groups and no new unexpected findings were found. Figure 1
Conclusion:
Our real world analysis further confirmed that bevacizumab-contained therapy as first line treatment was indeed superior in clinical benefits than non-bevacizumab regimen in Chinese patients with advanced NS-NSCLC in a real world.
